By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Efavirenz

Efavirenz

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|653 words

Efavirenz: HIV Treatment Medication

What is Efavirenz?

Efavirenz is an antiretroviral medication belonging to the class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is primarily used as part of combination therapy to treat HIV-1 infection in adults and children. This medication helps reduce the amount of HIV in the blood and supports immune system function when used consistently as prescribed.

Uses

  • HIV-1 infection treatment: Used in combination with other antiretroviral drugs to treat HIV-1 infection in adults and pediatric patients weighing at least 40 kg
  • Initial HIV therapy: Often prescribed as part of first-line treatment regimens for newly diagnosed HIV patients
  • Treatment-experienced patients: May be used in patients who have previously received HIV treatment, depending on resistance patterns
  • Preventing mother-to-child transmission: Sometimes included in regimens to reduce the risk of HIV transmission from mother to baby during pregnancy and childbirth
  • Post-exposure prophylaxis: Occasionally used as part of combination therapy following potential HIV exposure in certain high-risk situations

How it works

Efavirenz works by blocking HIV reverse transcriptase, an enzyme that the virus needs to reproduce itself inside human cells. By inhibiting this enzyme, efavirenz prevents HIV from making copies of its genetic material and integrating into the host cell’s DNA. This action helps reduce viral load and allows the immune system to recover and function more effectively.

Side effects

Common side effects:

  • Dizziness and lightheadedness
  • Vivid dreams and nightmares
  • Difficulty concentrating
  • Drowsiness or insomnia
  • Nausea and vomiting
  • Headache
  • Fatigue
  • Skin rash

Serious side effects requiring medical attention:

Submit Your Paper
GMJ_Submit_Banner
  • Severe psychiatric symptoms including depression, anxiety, or suicidal thoughts
  • Severe skin reactions including Stevens-Johnson syndrome
  • Liver problems with symptoms like yellowing of skin or eyes
  • Seizures or severe nervous system effects
  • Signs of immune reconstitution inflammatory syndrome

Warnings and precautions

  • Psychiatric effects: Patients with a history of mental health disorders should be closely monitored, as efavirenz can worsen depression, anxiety, and suicidal ideation
  • Pregnancy considerations: Efavirenz is generally avoided during the first trimester of pregnancy due to potential neural tube defects; women of childbearing age should use effective contraception
  • Liver function: Patients with hepatitis B or C co-infection require careful monitoring for liver toxicity during treatment
  • Drug resistance: Missing doses can lead to drug resistance, making the medication less effective over time
  • Central nervous system effects: Patients should avoid driving or operating machinery until they know how the medication affects them, especially during the first weeks of treatment

Interactions

  • Warfarin: Efavirenz may alter warfarin metabolism, requiring more frequent blood clotting monitoring and possible dose adjustments
  • Hormonal contraceptives: May reduce effectiveness of birth control pills, patches, or implants, requiring additional contraceptive methods
  • Rifampin: This tuberculosis medication can significantly reduce efavirenz blood levels, potentially requiring dosage adjustments
  • Antifungal medications: Drugs like voriconazole and itraconazole can have altered effectiveness when combined with efavirenz
  • Anticonvulsants: Medications like phenytoin and carbamazepine may interact with efavirenz, affecting seizure control
  • St. John’s Wort: This herbal supplement can significantly reduce efavirenz levels and should be avoided
  • Methadone: Efavirenz may reduce methadone levels, potentially requiring dose adjustments in patients receiving opioid maintenance therapy
  • Statins: Some cholesterol medications may have altered effectiveness or increased side effects when used with efavirenz

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dose is 600 mg taken once daily, preferably at bedtime to minimize central nervous system side effects. For pediatric patients weighing 40 kg or more, the adult dose applies. The medication should be taken on an empty stomach, preferably 1-2 hours before meals, as food can increase absorption and potentially worsen side effects. Efavirenz is always used in combination with other HIV medications, never alone. Dosage adjustments may be necessary for patients taking certain other medications or those with liver impairment. Always follow your healthcare provider’s specific dosing instructions.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Efavirenz." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/efavirenz/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
E-cigarettes deliberately designed to target youth through availability and addictive features, researchers warn

New research reveals how tobacco companies systematically design e-cigarettes to maximize youth…

FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Methylphenidate

By
Prof. Giorgi Pkhakadze
02/06/2026

Metronidazole

By
Prof. Giorgi Pkhakadze
02/06/2026

Mercaptopurine

By
Prof. Giorgi Pkhakadze
02/06/2026

Fluticasone

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up